{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:49Z","timestamp":1793647669496,"version":"4.5.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 CA232130"],"award-info":[{"award-number":["R35 CA232130"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["CA208108"],"award-info":[{"award-number":["CA208108"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["P01CA217798"],"award-info":[{"award-number":["P01CA217798"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.nucmedbio.2024.108976","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:18:37Z","timestamp":1732274317000},"page":"108976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer"],"prefix":"10.1016","volume":"140-141","author":[{"given":"Kyeara N.","family":"Mack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed I.","family":"Atmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara D.","family":"Viray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory L.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108976_bb0005","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.nucmedbio.2024.108976_bb0010","first-page":"28","article-title":"Ovarian Cancer","volume":"45","author":"Section","year":"2018","journal-title":"Am Cancer Soc"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0015","unstructured":"Centers for Disease Control and Prevention. Ovarian Cancer. http:\/\/www.cdc.gov\/cancer\/ovarian."},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0020","first-page":"635","article-title":"Ovarian cancer: diagnosis and treatment","volume":"108","author":"Burges","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0025","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/541842","article-title":"Diagnosis and management of peritoneal metastases from ovarian cancer","volume":"2012","author":"Halkia","year":"2012","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108976_bb0030","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.nucmedbio.2024.108976_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jso.21288","article-title":"Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer","volume":"99","author":"Sehouli","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/740472","article-title":"Targeted therapy in ovarian cancer","volume":"2010","author":"Willmott","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0055","doi-asserted-by":"crossref","first-page":"1073797","DOI":"10.3389\/fmolb.2022.1073797","article-title":"The potential of PARP inhibitors in targeted cancer therapy and immunotherapy","volume":"9","author":"Hunia","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100536","article-title":"Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?","volume":"7","author":"Musacchio","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0065","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fonc.2020.01204","article-title":"PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating PARP-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2 suppl","key":"10.1016\/j.nucmedbio.2024.108976_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2006.03.066","article-title":"Targeted radionuclide therapy for solid tumors: an overview","volume":"66","author":"DeNardo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"JCO"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0085","first-page":"2806","article-title":"A phase I study of combined modality (90)yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer","volume":"8","author":"Alvarez","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108976_bb0090","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/14737140.4.3.459","article-title":"Targeted alpha-therapy for control of micrometastatic prostate cancer","volume":"4","author":"Li","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108976_bb0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","article-title":"An overview of targeted alpha therapy","volume":"33","author":"Kim","year":"2012","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108976_bb0100","first-page":"693","article-title":"Targeted therapy of cancer with radiolabeled antibodies","volume":"43","author":"Goldenberg","year":"2002","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1440-1673.1999.00717.x","article-title":"Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer","volume":"43","author":"Allen","year":"1999","journal-title":"Australas Radiol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108976_bb0110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.cdd.4401047","article-title":"Ac-225 and her daughters: the many faces of Shiva","volume":"9","author":"McDevitt","year":"2002","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108976_bb0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1874471011666180416161908","article-title":"Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences","volume":"11","author":"Robertson","year":"2018","journal-title":"Curr Radiopharm"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0120","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.nucmedbio.2024.108976_bb0125","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213\u2013lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0130","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1002\/anie.200906294","article-title":"In vivo chemistry for pretargeted tumor imaging in live mice","volume":"49","author":"Rossin","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"10.1016\/j.nucmedbio.2024.108976_bb0135","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2967\/jnumed.117.189944","article-title":"Pretargeted imaging and therapy","volume":"58","author":"Altai","year":"2017","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108976_bb0140","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41596-023-00825-8","article-title":"Click chemistry: a transformative technology in nuclear medicine","volume":"18","author":"Bauer","year":"2023","journal-title":"Nat Protoc"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0145","doi-asserted-by":"crossref","unstructured":"Bauer D, Cornejo MA, Hoang TT, Lewis JS, Zeglis BM. Click chemistry and radiochemistry: an update. Bioconjug Chem 2023 Nov 15;34(11):1925\u20131950.","DOI":"10.1021\/acs.bioconjchem.3c00286"},{"issue":"8","key":"10.1016\/j.nucmedbio.2024.108976_bb0150","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2967\/jnumed.112.115840","article-title":"A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry","volume":"54","author":"Zeglis","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1535-7163.MCT-16-0503","article-title":"Establishment of the in vivo efficacy of Pretargeted Radioimmunotherapy utilizing inverse Electron demand Diels-Alder click chemistry","volume":"16","author":"Houghton","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.nucmedbio.2024.108976_bb0160","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-18-1650","article-title":"Leveraging bioorthogonal click chemistry to improve 225Ac-Radioimmunotherapy of pancreatic ductal adenocarcinoma","volume":"25","author":"Poty","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"45","key":"10.1016\/j.nucmedbio.2024.108976_bb0165","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing 64Cu\/67Cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.123.266388","article-title":"212Pb-Pretargeted Theranostics for pancreatic Cancer","volume":"65","author":"Bauer","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0175","doi-asserted-by":"crossref","first-page":"13518","DOI":"10.1021\/ja8053805","article-title":"Tetrazine ligation: fast bioconjugation based on inverse electron demand Diels-Alder reactivity","volume":"130","author":"Blackman","year":"2008","journal-title":"J Am Chem Soc"},{"issue":"11","key":"10.1016\/j.nucmedbio.2024.108976_bb0180","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2967\/jnumed.113.123745","article-title":"Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody","volume":"54","author":"Rossin","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0185","unstructured":"Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res 2003; 9(10):3914S\u201321S."},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnumed.120.243394","article-title":"TAG-72-targeted \u03b1-radionuclide therapy of ovarian Cancer using 225Ac-labeled DOTAylated-huCC49 antibody","volume":"62","author":"Minnix","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100873","article-title":"Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer","volume":"14","author":"Palm","year":"2020","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nucmedbio.2011.07.003","article-title":"Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model","volume":"39","author":"Gustafsson","year":"2012","journal-title":"Nucl Med Biol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2024.108976_bb0205","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijrobp.2007.06.023","article-title":"Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice","volume":"69","author":"Palm","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.nucmedbio.2024.108976_bb0210","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab\u2019)2 \u2013 a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0215","first-page":"12","article-title":"Pharmacokinetics and imaging of 212Pb-TCMC-Trastuzumab after intraperitoneal administration in ovarian cancer patients","volume":"29","author":"Meredith","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2024.108976_bb0220","unstructured":"Bauer D, DeGregorio R, Pratt EC, et al. Exploring the PET in vivo generator 134Ce as a theranostic match for 225Ac. BioRxiv doi: https:\/\/doi.org\/10.1101\/2024.04.25.591165v1."},{"issue":"39","key":"10.1016\/j.nucmedbio.2024.108976_bb0225","doi-asserted-by":"crossref","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","article-title":"Immature truncated O-glycophenotype of cancer directly induces oncogenic features","volume":"111","author":"Radhakrishnan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0230","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ymthe.2020.12.029","article-title":"Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer","volume":"29","author":"Thomas","year":"2021","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0235","first-page":"689","article-title":"Bone marrow dosimetry for Radioimmunotherapy: theoretical considerations","volume":"34","author":"Sgouros","year":"1993","journal-title":"JNM"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108976_bb0240","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0039-9140(02)00457-5","article-title":"SOLVERSTAT: a new utility for multipurpose analysis. An application to the investigation of dioxygenated co(II) complex formation in dimethylsulfoxide solution","volume":"59","author":"Comuzzi","year":"2003","journal-title":"Talanta"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108976_bb0245","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-21-1798","article-title":"ImmunoPET of ovarian and pancreatic Cancer with AR9.6, a novel MUC16-targeted therapeutic antibody","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108976_bb0250","first-page":"580","article-title":"Interrogating the Theranostic capacity of a MUC16-targeted antibody for ovarian Cancer","volume":"65","author":"Mack","year":"2024","journal-title":"JNM"},{"issue":"9","key":"10.1016\/j.nucmedbio.2024.108976_bb0255","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: a path forward for Radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J Nucl Med"},{"issue":"Suppl. 3","key":"10.1016\/j.nucmedbio.2024.108976_bb0260","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.2967\/jnumed.121.262749","article-title":"Dosimetry for radiopharmaceutical therapy: current practices and commercial resources","volume":"62","author":"Capala","year":"2021","journal-title":"J Nucl Med"},{"issue":"Suppl. 3","key":"10.1016\/j.nucmedbio.2024.108976_bb0265","doi-asserted-by":"crossref","first-page":"60S","DOI":"10.2967\/jnumed.121.262977","article-title":"Dosimetry in clinical radiopharmaceutical therapy of Cancer: practicality versus perfection in current practice","volume":"62","author":"Pandit-Taskar","year":"2021","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108976_bb0270","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph8030416","article-title":"Toxicological studies of 212Pb intravenously or intraperitoneally injected into mice for a phase 1 trial","volume":"8","author":"Milenic","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3\u20134 Suppl","key":"10.1016\/j.nucmedbio.2024.108976_bb0275","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1293\/tox.27.1S","article-title":"Nonproliferative and proliferative lesions of the rat and mouse female reproductive system","volume":"27","author":"Dixon","year":"2014","journal-title":"J Toxicol Pathol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2024.108976_bb0280","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-20-2150","article-title":"A self-assembling and disassembling (SADA) bispecific antibody (BsAb) platform for curative two-step pretargeted radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:05:40Z","timestamp":1762347940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":56,"alternative-id":["S0969805124001021"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108976","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108976"}}